OnDemand WTP Pricing Research

Drug makers resist pressure from Washington on prices | ABC7 News

President Donald Trump and Democratic lawmakers alike are pressuring drug makers to lower prices, but they don’t seem to be listening.

Sixty pharmaceutical companies kicked off 2019 by raising list prices on nearly 300 drugs, according to an analysis by Rx Savings Solutions. And more drug manufacturers are expected to quietly follow suit in coming weeks — a delay experts say appears calculated to avoid attracting undue attention from Washington.

Follow this story to get email or text alerts from ABC7 when there is a future article following this storyline.
“Companies are becoming more savvy about having the administration feel like they have a win,” said Stacie Dusetzina, a health policy researcher at Vanderbilt University.

Trump, who has made controlling drug price increases a priority, continues to insist that he can get drug makers to lower prices. He noted at Wednesday’s Cabinet meeting that the Department of Health & Human Services is “almost ready to make that big final push” to address the issue.

“We’ve done an incredible job,” the President said. “I think you’re gonna see a tremendous reduction in drug prices.”

Administration officials rolled out a 44-page blueprint last May that laid out the President’s vision for increasing competition, reducing regulations and changing incentives for players in the industry.

Much of what the Department of Health & Human Services has done so far consists of putting forward proposals, largely involving what Medicare will pay for medications.

One of the more significant plans would set the reimbursement level for certain drugs administered in doctors’ offices and hospital outpatient centers based on their cost in other countries, which typically pay far less. The so-called International Pricing Index model has already faced blow back from many quarters, including Republican lawmakers.

But so far, most of the efforts have been on the margins.

“The rhetoric they are using is out of scale with their proposals,” said Rachel Sachs, an associate law professor at Washington University who studies drug pricing.

Read complete article here:

Drug makers resist pressure from Washington on prices – ABC7 News.